



Adropin- A Novel Biomarker of Heart Disease: A Systematic Review Article

Somaye YOSAEI^{1,2}, *Sepideh SOLTANI*¹, *Eghbal SEKHAVATI*³, **Shima JAZAYERI*^{1,4}

1. Dept. of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
2. Emaz School of Health, Larestan School of Medical Sciences, Larestan, Iran
3. Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4. Research Center for Prevention of Cardiovascular Disease, Iran University of Medical Sciences, Tehran, Iran

***Corresponding Author:** Email: sh_jaz@yahoo.com

(Received 03 Feb 2016; accepted 10 Jul 2016)

Abstract

Background: Heart disease is one of the most common chronic disease and leading cause of morbidity and mortality worldwide. Adropin, a newly identified protein, is important for energy homeostasis and maintaining insulin sensitivity, and has been referred to as a novel regulator of endothelial cells. Endothelial dysfunction is a key early event in atherogenesis and onset of HD. Therefore, this review gives a systematic overview of studies investigating plasma adropin level in patient with heart disease.

Methods: Data carried out in PubMed, Scopus, Web of Science, Embase, Google scholar and MEDLINE, from the earliest available online indexing year through 2015. The search restricted to studies conducted in humans. The keyword search was adropin to apply in title, abstract and keywords. References lists of all original published articles were scanned to find additional eligible studies.

Results: Heart failure (HF), coronary atherosclerosis acute myocardial infarction and Cardiac Syndrome X (CSX) were type of heart disease acknowledged in this study. Majority of evidences introduced low adropin as an independent risk factor of heart disease. In a case-control study, the plasma level of adropin increased with the severity of HF.

Conclusion: Adropin may be a potential serum biomarker for early diagnosis of HD.

Keywords: Adropin, Heart, Endothelium, Systematic review

Introduction

Despite modern medical management, heart disease is still one of the most common chronic diseases and remains the leading cause of morbidity and mortality worldwide. Accurate diagnosis of HD improve prognosis through early treatment. Although, current strategy for prognosis of HD is good, however, are not enough to explain all coronary events. Therefore, researches for potential novel its risk factors and diagnostic criteria are requirement to be fulfilled (1-4).

Adropin is a recently identified protein encoded by the energy homeostasis-associated gene (Enho) identified during an investigation of obese

insulin resistant mice as a novel factor linking with metabolic homeostasis (5). Adropin appears to participate in the maintenance of energy homeostasis and insulin response, closely related to the development and progression of atherogenesis (5). Lower adropin level leads to endothelial impairment and dysfunction (6). Endothelial dysfunction is a key early event in atherogenesis and onset of HD (7). Furthermore, low serum adropin introduced as an independent predictor of clinically relevant coronary atherosclerosis (8). We hypothesized that adropin may have a potential role in the pathophysiology of HD.

The aim of this present study was to investigate the effects of adropin on HD through systematic review.

Material and Methods

Search strategy

We performed a systematic search of PubMed, Scopus, web of science, Embase, Google scholar and MEDLINE for studies examining the association between serum adropin levels and all type of heart disease. The keyword search was adropin to apply in title, abstract and keywords. The search strategies for the other databases were identical. The search was restricted to English article conducted in humans. The PRISMA 2009 guidelines for systematic review and meta-analysis were considered throughout the study. References lists of all original published articles were scanned to find additional eligible studies.

Study selection

The predetermined inclusion criteria were: 1) exposure introduced as serum adropin levels; 2) the outcome interest was all type of heart disease; 3) studies that conducted in adult population were not endocrine disorders. Studies were excluded if they were pregnant and lactating women or reviews, editorial, letters, meeting abstract and animal study. Studies screened independently by two investigators (SY, SS) based on the inclusion criteria with a low probability to exclude irrelevant abstract. Disagreements about inclusion of studies were settling after investigators expressed their opinion.

Overall, 220 abstracts were retrieved by searching in the electronic database. Of those, 151 abstracts were duplicated, 27 did not study coronary heart disease as interesting outcome (5, 9-34), 3 were editorial and review (35-37), 13 were non-human studies (6, 38-49), 8 were Meeting abstract (50-57) and 12 conducted in children, pregnant and lactating women (58-69). After final screening of full text, six articles were eligible to address in this systematic review (8, 70-74), which four of

those were case-control (8, 72-74) studies and 2 articles were cross-sectional studies (70, 71).

Data extraction

Two authors conducted independently data extraction using a pre-formatted spreadsheet. All data extracted we rescanned two times. If there were discrepancies, group consensus and consulted a third reviewer were used to reach a ensure accuracy of data. The data extracted included: study characteristics (authors, year of publication, study location, study design) the participants' age, number of allocated participants, serum adropin level, type of heart disease, adropin assessment method. The Newcastle-Ottawa scales, validated scale for non-randomized studies were applied to examine the quality of included evidences. This scale awards a maximum of nine points to each study.

Results

Table 1 exhibited detail of study and participants characterize. Heart failure (HF), coronary atherosclerosis acute myocardial infarction and Cardiac Syndrome X (CSX) were type of heart disease acknowledged in this study. All studies were conducted on both sex, two studies conducted in Turkey (70, 71), and four investigation were from China (8, 72-74).

There were significant differences in the plasma adropin level between heart disease patients with healthy participants. Majority of evidences introduced low adropin as an independent predictor of heart disease (8, 70, 71, 73, 74). In a case-control study, the plasma level of adropin increased with the severity of HF (control: 6.0 ± 0.3 ng/mL; HA functional Class II: 7.6 ± 0.4 ; HA functional Class III: 9.8 ± 0.5 ; HA functional Class IV: 12.4 ± 0.6 ng/mL ($P < 0.01$) (72). In a similar design, reported the stable angina pectoris (SAP) and acute myocardial infarction compare with control group have lower serum adropin (74).

Adropin could be a predictor serum biomarker of early diagnosis of AMI (74).

Table 1: Characteristic of studies that evaluated of adropin status in patient with coronary artery disease

Reference number	Number of participant	Age range (year)	measurements	Mean of BMI (kg/m ²)	Mean of adropin (ng/ml)
74	108 AMI patients, 114 stable angina pectoris (SAP) patients and 75 controls	AMI: 64.50 ± 10.53 SAP: 63.67 ± 11.18 Control: 60.40 ± 9.58	TC, TG, HDL, LDL, hs-CRP, proBNP, cTnT, Adropin, troponin I, ECG,	AMI: 25.07 SAP:25.12 Control:24.74	AMI: 2.19±1.61 SAP: 3.81±1.78 Control: 5.12±1.44
72	56 heart failure patients (HF) and 20 health person as control	HF:76.8 ± 7.6 Range 60-92 yr Control: mean age 72.4 ± 8.4 yr, range 57-82 yr	Fasting plasma glucose (FBG), lipids, creatinine (Cr), blood urea nitrogen (BUN), TC, TG, LDL, HDL, adropin, brain natriuretic peptide (BNP), tumor necrosis factor α (TNF- α) and interleukin 6 (IL-6)	Con-trol:24.2±0.07 NY- HAI:22.8±0.6 NY- HAI:24.4±1.0 NY- HAI:23.4±0.9	Control: 6±0.3 NYHAI: 7.6±0.4 NYHAI: 9.8±0.5 NYHAI:12.4±0.6
8	392 patients with suspected coronary artery disease	Non diabetic patient: 63.09±10.84 Diabetic patient: 63.2±9.88	Coronary angiograph, Fasting blood glucose (FBG), serum total cholesterol (TC), triglycerides (TG), low and high density lipoprotein cholesterol (LDL-C, HDL-C), creatinine and uric acid, HbA1c, hs-CRP, adropin	Non diabetic patient: 31.13 Diabetic patient: 34.44	Non diabetic patient: 5.53 Diabetic patient: 4.8
70	Thirty-eight patients with SVGD involving at least onegraft(occluded group; 14 females, 24 males) and 42 patients with apatent saphenous vein graft (patent group; 15 females, 27males)	occluded group: mean age 62.0 ± 9.7 yr patent group: 60.0 ± 12.0 yr	Coronary angiography, Adropin, Fasting plasma glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol and triglyceride, CRP, blood pressure	occluded group: 26 ± 5.1 patent group: 25.3 ± 5.9	occluded group: 3.2±0.71 patent group: 4.9±1.51
71	86 consecutive Cardiac Syndrome X-diagnosed patients (CSX) and 86 age-sex matched healthy subjects	Cardiac Syndrome X: 54.8±9.2 Control: 52.7±8.5	Serum adropin levels, nitrite/nitrate Levels, exercise treadmill testing	Cardiac Syndrome X: 28.1±2.4 Control: 26.0±3.7	Cardiac Syndrome X: 1.7±0.8 Control: 3.4±1.8
73	116patientswithSCADand116controlsubjectswithoutcoronaryarterydisease	pa-tientswithSCAD:64.1±11.4 control:62.8±12.6	BMI, Cholesterol, TG, LDL, HDL, Bloodureanitrogen, Creatinine, hs-CRP, FBS, insulin, adropin	pa-tientswithSCAD: 25.0±3.8 control: 23.9±3.5	patientswithSCAD: 59.2±19.3 control: 70.0±18.2

A decrease in adropin level found in patients with CSX than control participants (1.7 ± 0.8 ng/mL and 3.4 ± 1.8 ng/mL, respectively; $P < 0.001$). Additionally, adropin was one of the predictor risk factors for CSX ($\beta = -0.104$, P -value = 0.005) (71). Patients with stable coronary artery disease (SCAD) had lower serum adropin levels compared to the controls (59.2 ± 19.3 versus 70.0 ± 18.2 pg/mL, $P < 0.001$).

Moreover, low serum adropin level was introduced as a predictor of SCAD (73). In a cross-sectional study, serum adropin was inversely associated with the score of severity of coronary atherosclerosis assessed by Gensini, Friesinger,

and SYNTAX scores. A decrease serum adropin indicated a negative independent predictor of coronary atherosclerosis (as SYNTAX score > 11) (8). In similar design study introduced lower serum adropin as an independent predictor of Saphenous Vein Graf Disease (SVG D) after coronary artery bypass grafting (OR = 0.558, 95% CI = 0.433-0.714, $P < 0.01$) (70).

Discussion

Adropin is a newly identified protein that its protective role on endothelial cells has been shown previously, and has been referred to as a novel

regulator of these cells (46). The key findings from the present review study were that there were significant differences in the plasma adropin level between patients with heart disease (AMI, SAP, atherosclerosis, Cardiac Syndrome X, occluded SVG) and control subjects. Furthermore, serum adropin inversely is associated with angiographic severity of coronary atherosclerosis. Serum adropin level may be referred to as a novel biomarker for evaluation and follow up in patients with HD.

Several mechanisms have been suggested to explain adropin effect in HD patients. Endothelial dysfunction has been introduced as main mechanism (75). The endothelium plays a crucial role in the maintenance of vascular homeostasis, and endothelial dysfunction contributes to the development and progression of cardiovascular diseases (71). Low adropin is associated with endothelial dysfunction (6, 13, 25). Furthermore, adropin can exert protective effects on the endothelial function (6).

Nitric oxide, a potent endogenous vasodilator formed in the endothelium by the endothelial isoform of eNOS, plays an important role in maintaining endothelial homeostasis (71). Nitric oxide furthermore inhibits monocytes and leukocytes adhesion to the endothelium, aggregation of platelets, oxidation of low density lipoprotein, and smooth muscle cell proliferation (76-79). Low levels of nitric oxide are associated with endothelial dysfunction. Adropin has a protective and regulator role on endothelial function (6). Adropin could enhance the expression of endothelial nitric oxide synthase (eNOS), responsible for the production of vascular nitric oxide, in the endothelium, so adropin deficiency is associated with reduced nitric oxide bioavailability in the endothelium (74, 80). Loss of NO bioavailability is a critical stage in formation of endothelial dysfunction that is an independent predictor of the onset of coronary artery disease (81). Patients with Cardiac Syndrome X, characterized by endothelial dysfunction, compared to healthy subjects had significantly lower adropin levels (71).

Besides, the reduced circulating adropin concentrations participates in metabolic disorders such

as insulin resistance (5, 13) related to the onset and progression of coronary atherosclerosis and increased incidence rate of cardiovascular events (82, 83).

C-reactive protein has been widely used for cardiovascular risk stratification (27-29). A negative correlation between adropin and hs-CRP levels was found (8). Atherosclerosis has been regarded as a chronic inflammatory disease, so adropin as a potential anti-inflammatory protein play an important role in the prevention of atherosclerosis (8).

However, plasma adropin levels were correlated positively with BMI and the severity of heart failure, which is in contrary to our results (72). Cardiac cachexia which characterized by weight loss, muscle wasting and cytokine activation frequently occurs in patients with advanced HF (84). Liver Enho expression decreases with either diet or genetically induced obesity (5). Besides, cardiac cachexia or wasting, which could reflect a decrease in visceral fat, may be result in the elevation of plasma adropin levels in patients with HF.

Conclusion

Adropin may serve as a potential biomarker for early diagnosis of and severity stratification HD.

Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgments

The research group thanks Dr. Mohammadreza Vafafor his contribution to our manuscript. The authors declare that there is no conflict of interests.

Reference

1. Fuster V, Kovacic JC (2014). Acute Coronary Syndromes Pathology, Diagnosis, Genetics,

- Prevention, and Treatment. *Circ Res*,114(12):1847-51.
2. Pope JH, Aufderheide TP, Ruthazer R, Woolard RH, Feldman JA, Beshansky JR, et al (2000). Missed diagnoses of acute cardiac ischemia in the emergency department. *N Engl J Med*, 342(16):1163-70.
 3. Swap CJ, Nagurney JT (2005). Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes. *JAMA*, 294(20):2623-9.
 4. Vasani RS (2006). Biomarkers of cardiovascular disease: molecular basis and practical considerations. *Circulation*, 113(19):2335-62.
 5. Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al (2008). Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. *Cell Metab*, 8(6):468-81.
 6. Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, et al (2010). Adropin is a novel regulator of endothelial function. *Circulation*, 122(11 Suppl):S185-92.
 7. Kathir K, Adams MR, (2003). Endothelial dysfunction as a predictor of acute coronary syndromes. *Semin Vasc Med*, 3(4): 355-362.
 8. Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al. (2014). Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. *Clin Chem Lab Med*, 52(5):751-8.
 9. Kumar G, Halem H, Culler M, Stephens J, Mynatt R, Butler A (2008). Adropin-a Novel Secreted Factor Involved in Lipid Homeostasis. *Obesity*, nature publishing group 75 varick st, 9th flr, New York, NY10013-1917 USA.
 10. Kumar K, Zhang J, Mynatt R, Butler A (2009). Adropin-a novel secreted factor linking diet with energy homeostasis. *Biopolymers*, John Wiley & Sons Inc 111 river st, Hoboken, New Jersey, NJ 07030 USA.
 11. Sanchis-Gomar F, Alis R, Rampinini E, Bosio A, Ferioli D, La Torre A, et al (2015). Adropin and apelin fluctuations throughout a season in professional soccer players: Are they related with performance? *Peptides*, 70:32-6.
 12. Chen M, Ouyang F, Zhou S (2015). Adropin as a novel energy factor likely has the ability to regulate blood pressure. *Med Hypotheses*, 85(2):234.
 13. Ganesh-Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, et al (2012). Adropin deficiency is associated with increased adiposity and insulin resistance. *Obesity (Silver Spring)*, 20(7):1394-402.
 14. Lian A, Wu K, Liu T, Jiang N, Jiang Q (2016). Adropin induction of lipoprotein lipase expression in tilapia hepatocytes. *J Mol Endocrinol*, 56(1):11-22.
 15. Kumar KG, Jingying Z, Mynatt RL, Butler AA, editors (2010). Adropin Is Required for Maintaining Glucose Homeostasis. *Diabetes*, amer diabetes assoc 1701 n beauregard st, alexandria, Vancouver, VA 22311-1717 USA.
 16. Yildirim B, Celik O, Aydin S (2014). Adropin: a key component and potential gatekeeper of metabolic disturbances in polycystic ovarian syndrome. *Clin Exp Obstet Gynecol*, 41(3):310-2.
 17. Fujie S, Hasegawa N, Sato K, Fujita S, Sanada K, Hamaoka T, et al (2015). Aerobic exercise training-induced changes in serum adropin level are associated with reduced arterial stiffness in middle-aged and older adults. *Am J Physiol Heart Circ Physiol*, 309(10):H1642-47.
 18. Gozal D, Kheirandish-Gozal L, Bhattacharjee R, Molero-Ramirez H, Tan H-L, Bandla HP (2013). Circulating adropin concentrations in pediatric obstructive sleep apnea: potential relevance to endothelial function. *J Pediatr*, 163(4):1122-6.
 19. Nergiz S, Altinkaya SO, Kurt Ömürlü İ, Yuksel H, Küçük M, Demircan Sezer S (2015). Circulating adropin levels in patients with endometrium cancer. *Gynecol Endocrinol*, 31(9):730-5.
 20. Zapata RC, Salehi R, Ambrose DJ, Chelikani PK (2015). Effects of prepartum fat supplementation on plasma concentrations of glucagon-like peptide-1, peptide YY, adropin, insulin, and leptin in periparturient dairy cows. *J Dairy Sci*, 98(10):6876-85.
 21. Yolbas S, Kara M, Yildirim A, Gundogdu B, Kalayci M, Aydin S, et al (2014). THU0489 Enho Gene Expression and Serum Adropin Level in Rheumatoid Arthritis and Systemic Lupus Erythematosus. *Ann Rheum Dis*, 73:352-3.

22. St-Onge MP, Shechter A, Shlisky J, Tam CS, Gao S, Ravussin E, et al. (2014). Fasting plasma adropin concentrations correlate with fat consumption in human females. *Obesity (Silver Spring)*, 22(4):1056-63.
23. Stein L, Samson W, Yosten G (2015). Identification of a Candidate Adropin Receptor. *FASEB J*, 29(1 Supplement):997.5.
24. Gu X, Li H, Zhu X, Gu H, Chen J, Wang L, et al (2015). Inverse Correlation Between Plasma Adropin and ET-1 Levels in Essential Hypertension: A Cross-Sectional Study. *Medicine (Baltimore)*, 94(40):e1712.
25. Butler AA, Tam CS, Stanhope KL, Wolfe BM, Ali MR, O'Keeffe M, et al (2012). Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. *J Clin Endocrinol Metab*, 97(10):3783-91.
26. Sánchez-de-la-Torre M, Khalyfa A, Sánchez-de-la-Torre A, Martínez-Alonso M, Martínez-García MÁ, Barceló A, et al (2015). Precision medicine in patients with resistant hypertension and obstructive sleep apnea: blood pressure response to continuous positive airway pressure treatment. *J Am Coll Cardiol*, 66(9):1023-32.
27. Demircelik B, Kurtul A, Ocek H, Cakmak M, Cetin M, Ureyen C, et al (2015). The Relationship Between Adropin Levels and the Slow Coronary Flow Phenomenon. *Ind J Clin Biochem*, 30(4):412-417.
28. Yolbas S, Kara M, Yilmaz M, Aydin S, Koca S, editors (2014). Serum adropin level and enho expression in systemic sclerosis. Clinical and experimental rheumatology, clinical & exper rheumatology via santa maria 31, 56126 PISA, ITALY.
29. Aydin S, Kuloglu T, Aydin S, Kalayci M, Yilmaz M, Cakmak T, et al (2014). A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues. *Peptides*, 61:130-6.
30. Butler AA, St-Onge M-P, Siebert EA, Medici V, Stanhope KL, Havel PJ (2015). Differential Responses of Plasma Adropin Concentrations To Dietary Glucose or Fructose Consumption In Humans. *Sci Rep*, 5:14691.
31. Kheirandish-Gozal L, Gileles-Hillel A, Alonso-Álvarez M, Peris E, Bhattacharjee R, Terán-Santos J, et al (2015). Effects of adenotonsillectomy on plasma inflammatory biomarkers in obese children with obstructive sleep apnea: A community-based study. *Int J Obes (Lond)*, 39(7):1094-100.
32. Kuloglu T, Aydin S, Eren MN, Yilmaz M, Sahin I, Kalayci M, et al (2014). Irisin: a potentially candidate marker for myocardial infarction. *Peptides*, 55:85-91.
33. Kuhla A, Hahn S, Butschkau A, Lange S, Wree A, Vollmar B (2013). Lifelong caloric restriction reprograms hepatic fat metabolism in mice. *J Gerontol A Biol Sci Med Sci*, 69(8):915-22.
34. Gao S, McMillan RP, Jacas J, Zhu Q, Li X, Kumar GK, et al (2014). Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. *Diabetes*, 63(10):3242-52.
35. Goetze JP, Albrethsen J (2014). Adropin: a new regulatory peptide in cardiovascular endocrinology. *Regul Pept*, 190-191:41-2.
36. Aydin S (2014). Three new players in energy regulation: preptin, adropin and irisin. *Peptides*, 56:94-110.
37. Puzio I, Tymicki G, Pawłowska M, Puzio A, Śleboda W (2015). Role of adropin in cardiovascular physiology. *Med Weter*, 71(10):599-601.
38. Akcilar R, Kocak FE, Simsek H, Akcilar A, Bayat Z, Ece E, et al editors (2015). Antidiabetic and Hypolipidemic Effects of Adropin in Streptozotocin-induced Type 2 Diabetic Rats. *Acta Physiol*, wiley –blackwell 111 river st, hoboken 07030-5774, New Jersi, NJ USA.
39. Aydin S (2013). Presence of adropin, nesfatin-1, apelin-12, ghrelins and salusins peptides in the milk, cheese whey and plasma of dairy cows. *Peptides*, 43:83-7.
40. Aydin S, Eren M, Kuloglu T, Aydin S, Yilmaz M, Gul E, et al (2015). Alteration of serum and cardiac tissue adropin, copeptin, irisin and TRPM2 expressions in DOX treated male rats. *Biotech Histochem*, 90(3):197-205.
41. Aydin S, Kuloglu T, Aydin S, Eren MN, Yilmaz M, Kalayci M, et al (2013). Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-

- induced diabetes. *Mol Cell Biochem*, 380(1-2):73-81.
42. Aydin S, Kuloglu T, Aydin S, Kalayci M, Yilmaz M, Çakmak T, et al (2014). Elevated adropin: a candidate diagnostic marker for myocardial infarction in conjunction with troponin-I. *Peptides*, 58:91-7.
 43. Bremer AA, Stanhope KL, Graham JL, Cummings BP, Ampah SB, Saville BR, et al (2014). Fish oil supplementation ameliorates fructose-induced hypertriglyceridemia and insulin resistance in adult male rhesus macaques. *J Nutr*, 144(1):5-11.
 44. Catak Z, Aydin S, Sahin I, Kuloglu T, Aksoy A, Dagli AF (2014). Regulatory neuropeptides (ghrelin, obestatin and nesfatin-1) levels in serum and reproductive tissues of female and male rats with fructose-induced metabolic syndrome. *Neuropeptides*, 48(3):167-77.
 45. Gao S, McMillan RP, Zhu Q, Lopaschuk GD, Hulver MW, Butler AA (2015). Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. *Mol Metab*, 4(4):310-24.
 46. Kuloglu T, Aydin S (2014). Immunohistochemical expressions of adropin and inducible nitric oxide synthase in renal tissues of rats with streptozotocin-induced experimental diabetes. *Biotech Histochem*, 89(2):104-10.
 47. Stein L, Samson W, Yosten G (2014). Adropin Enhances Glucose Disposal and Cardiovascular Function in Rats (LB761). *FASEB J*, 28(1).
 48. Wang SP, Gao YI, Gang L, Dun D, Chen RJ, Zhang YZ, et al (2015). Molecular cloning, characterization and expression of the energy homeostasis associated gene in piglet. *J Zhejiang Univ Sci B*, 16(6):524-32.
 49. Wong C-M, Wang Y, Lee JTH, Huang Z, Wu D, Xu A, et al (2014). Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice. *J Biol Chem*, 289(37):25976-86.
 50. Lovren F, Pan Y, Quan A, Singh K, Shukla P, Al-Omran M, et al (2009). Adropin is a Novel and Potent Endogenous Angiogenic Neuroendocrine Peptide: Abstract # 4746. American College of Cardiology Foundation and the American Heart Association. Michael's Hosp, Toronto, Canada. *Circulation*, 120:S998.
 51. Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Al-Omran M, et al (2010). Mechanistic insights into the actions of adropin, a novel regulator of endothelial function. *Can J Cardiol*, 26:82D-D.
 52. Lovren F, Pan Y, Quan A, Singh K, Shukla P, Al-Omran M, et al (2010). Adropin is a Novel Regulator of Endothelial Function Through the VEGFR2- PI3K-Akt and VEGFR2-Erk1/2 Pathways: Abstract # 13928. American College of Cardiology Foundation and the American Heart Association. Michael's Hosp, Toronto, Canada. *Circulation*, 122:A13928.
 53. Niepolski L, Sowinska A, Grzegorzewska A (2015). Circulating Adropin Concentration in Dyslipidemic and Non-Dyslipidemic Hemodialysis Patients: Abstract # 187.9th International Congress of the International Society for Hemodialysis: Global Challenges in Hemodialysis. Kuala Lumpur, Malaysia.
 54. Niepolski L, Sowinska A, Grzegorzewska A (2015). Circulating Adropin Concentration in Hemodialysis Patients: Relevance To Endothelial Receptors: Abstract # 119.9th International Congress of the International Society for Hemodialysis: Global Challenges in Hemodialysis. Kuala Lumpur, Malaysia.
 55. Niepolski L, Sowinska A, Grzegorzewska A (2015). Circulating Adropin Concentration in Hemodialysis Patients: Relation To Residual Diuresis and Metabolic Disturbances: Abstract # 118.9th International Congress of the International Society for Hemodialysis: Global Challenges in Hemodialysis. Kuala Lumpur, Malaysia.
 56. Silva AP, Fragoso A, Guilherme P, Silva C, Santos N, Rato F, et al (2014). FGF-23, magnesium and adropin as new risk factors of subclinical atherosclerosis in type 2 diabetic with 3 and 4 stages chronic kidney disease. *Nephrol Dial Transplant*, 29: 431-431.
 57. Tam C, Ravussin E, Onge M-PS, Butler A, editors (2011). A Preliminary Analysis of Serum Adropin Levels in Humans. *Obesity*, nature publishing group 75 varick st, 9 th flr, New York, NY 10013-1917 USA.
 58. Aydin HI, Eser A, Kaygusuz I, Yildirim S, Celik T, Gunduz S, et al (2016). Adipokine, adropin

- and endothelin-1 levels in intrauterine growth restricted neonates and their mothers. *J Perinat Med*, 44(6):669-76.
59. Kocaoglu C, Buyukinan M, Erdem SS, Ozel A (2015). Are obesity and metabolic syndrome associated with plasma adropin levels in children? *J Pediatr Endocrinol Metab*, 28(11-12):1293-7.
 60. Altincik A, Sayin O (2015). Evaluation of the relationship between serum adropin levels and blood pressure in obese children. *J Pediatr Endocrinol Metab*, 28(9-10):1095-100.
 61. Gileles-Hillel A, Alonso-Álvarez ML, Kheirandish-Gozal L, Peris E, Cordero-Guevara JA, Terán-Santos J, et al (2014). Inflammatory markers and obstructive sleep apnea in obese children: the NANOS study. *Mediators Inflamm*, 2014:605280.
 62. Sayin O, Tokgöz Y, Arslan N (2014). Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. *J Pediatr Endocrinol Metab*, 27(5-6):479-84.
 63. Wilmott RW (2013). Plasma adropin levels in children with obstructive sleep apnea. *J Pediatr*, 163(4):929-31.
 64. Qiu X, He J-R, Zhao M-G, Kuang Y-S, Xu S-Q, Zhang H-Z, et al (2014). Relationship between human cord blood adropin levels and fetal growth. *Peptides*, 52:19-22.
 65. Baka S, Malamitsi-Puchner A, Briana DD, Boutsikou M, Marmarinos A, Gourgiotis D, et al (2016). Adropin concentrations in term pregnancies with normal, restricted and increased fetal growth. *J Matern Fetal Neonatal Med*, 29(15):2403-7.
 66. Beigi A, Shirzad N, Nikpour F, Nasli Esfahani E, Emamgholipour S, Bandarian F (2015). Association between serum adropin levels and gestational diabetes mellitus; a case-control study. *Gynecol Endocrinol*, 31(12):939-41.
 67. Aydin S, Celik O, Gurates B, Sahin İ, Ulas M, Yilmaz M, et al (2013). Concentrations of preptin, salusins and hepcidins in plasma and milk of lactating women with or without gestational diabetes mellitus. *Peptides*, 49:123-30.
 68. Aydin S, Kuloglu T, Aydin S (2013). Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus. *Peptides*, 47:66-70.
 69. Celik E, Yilmaz E, Celik O, Ulas M, Turkcuoglu I, Karaer A, et al (2013). Maternal and fetal adropin levels in gestational diabetes mellitus. *J Perinat Med*, 41(4):375-80.
 70. Demircelik B, Cakmak M, Nazli Y, Gurel OM, Akkaya N, Cetin M, et al (2014). Adropin: a new marker for predicting late saphenous vein graft disease after coronary artery bypass grafting. *Clin Invest Med*, 37(5):E338-44.
 71. Celik A, Balin M, Kobat MA, Erdem K, Baydas A, Bulut M, et al (2013). Deficiency of a new protein associated with cardiac syndrome X; called adropin. *Cardiovasc Ther*, 31(3):174-8.
 72. Lian W, Gu X, Qin Y, Zheng X (2011). Elevated plasma levels of adropin in heart failure patients. *Intern Med*, 50(15):1523-27.
 73. Zhao L-P, Xu W-T, Wang L, You T, Chan S-P, Zhao X, et al (2015). Serum Adropin Level in Patients with Stable Coronary Artery Disease. *Heart, Lung Circ*, 24(10):975-9.
 74. Yu H-y, Zhao P, Wu M-c, Liu J, Yin W (2014). Serum adropin levels are decreased in patients with acute myocardial infarction. *Regul Pept*, 190 (31):46-9.
 75. Vázquez-Rey E, Kaski JC (2003). Cardiovascular syndrome X and endothelial dysfunction. *Rev Esp Cardiol*, 56(02):181-92.
 76. Kubes P, Suzuki M, Granger D (1991). Nitric oxide: an endogenous modulator of leukocyte adhesion. *Proc Natl Acad Sci*, 88(11):4651-5.
 77. Wolf A, Zalpour C, Theilmeier G, Wang B-y, Ma A, Anderson B, et al (1997). Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. *J Am Coll Cardiol*, 29(3):479-85.
 78. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S (1993). Inhibition of low-density lipoprotein oxidation by nitric oxide Potential role in atherogenesis. *FEBS Lett*, 334(2):170-4.
 79. Böger RH, Bode-Böger SM, Kienke S, Stan AC, Nafe R, Frölich JC (1998). Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. *Atherosclerosis*, 136(1):67-77.
 80. Ignarro L (2002). Nitric oxide as a unique signaling molecule in the vascular system: a

- historical overview. *J Physiol Pharmacol*, 53(4):503-14.
81. Alp NJ, Channon KM (2004). Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. *Arterioscler Thromb Vasc Biol*, 24(3):413-20.
82. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al (2010). The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. *J Am Coll Cardiol*, 56(14):1113-32.
83. Bayturan O, Tuzcu EM, Lavoie A, Hu T, Wolski K, Schoenhagen P, et al (2010). The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. *Arch Intern Med*, 170(5):478-84.
84. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al (1997). Wasting as independent risk factor for mortality in chronic heart failure. *Lancet*, 349(9058):1050-53.